Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics (Biomarkers) of ASC41 Tables in Overweight and Obese Subjects

The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .

Key Inclusion Criteria:

• 23kg/m2 ≤ BMI <40kg/m2.

Key Exclusion Criteria:

• A history of thyroid disease.
• A positive HBsAg, HCV Ab and/or HIV Ab.